Next 10 |
home / stock / dare / dare articles
Shares of James Hardie Industries plc (NYSE:JHX) fell sharply during Tuesday's session after the company reported worse-than-expected quarterl...
Bayer AG (OTC:BAYRY) (OTC:BAYZF) will present detailed results from the Phase 3 studies OASIS 1 and 2, showing that the investi...
Shares of H&E Equipment Services, Inc. (NASDAQ:HEES) fell sharply during Tuesday's session following mixed first-quarter results. H&E ...
Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as w...
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Dare? Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced ...
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced i...
Daré Bioscience Inc (NASDAQ: DARE) announced topline results from the Phase 1 DARE-PDM1-001 study evaluating the pharmacokinetics (PK),...
DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options Up to appro...
Daré Bioscience Inc (NASDAQ: DARE) announced that the FDA has cleared its investigational new drug (IND) application for DARE-VVA1 as a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...